☆ 4.7 Meeting Abstract

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

BLOOD (2019)

Journal

BLOOD

Volume 134, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2019-125102

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, Research & Experimental

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma

Qingzhu Jia, Diyuan Qin, Feng He, Qichao Xie, Zhitao Ying, Yajing Zhang, Yuqin Song, Jia-Nan Cheng, Xuejiao Zuo, Luxiang Xu, Hongliang Fang, Chunyan Hu, Lina Peng, Tao Jin, Zixiao Shi, Peter B. Alexander, Yongsheng Wang, Yarong Liu, Weidong Han, Jun Zhu, Pin Wang, Qi-Jing Li, Bo Zhu

Summary: This study identified the baseline high eosinophil count as a potential biomarker for predicting the clinical efficacy of CAR-T cell therapy in B-NHL patients. A preclinical model demonstrated that depletion of eosinophils could impair the intratumoral infiltration and antitumor efficacy of CAR-T cells.

THERANOSTICS (2021)

Add to Collection

Review Oncology

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Adrian Minson, Constantine Tam, Michael Dickinson, John F. Seymour

Summary: Targeted therapies have greatly improved the treatment options and outcomes for patients with indolent lymphomas. There are now numerous approved agents for use in these lymphomas, and ongoing development of other drugs shows significant promise. This article reviews the landscape of targeted agents for indolent lymphomas, including small molecule inhibitors, immunomodulators, targeted immunotherapies, and emerging combination therapies.

CANCERS (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies

Mark B. Leick, Marcela Maus, Matthew J. Frigault

Summary: Large B cell lymphoma can be cured with standard chemoimmunotherapy in most cases, but patients with refractory or relapsed disease have limited treatment options historically. Two gene-modified CAR-T cell therapies have been approved for these indications. Clinical decisions and management surrounding these gene-modified "living drugs" are nuanced and complex, involving factors such as patient selection, screening procedures, and follow-up.

MOLECULAR THERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas

Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Lara Ruoff, Christian Martin Seitz, Patrick Schlegel

Summary: CD19CAR T cells show promising results in treating relapsed and refractory aggressive B-lineage cancers. The AdCAR technology allows multitargeting and flexibility in adapting to different antigen profiles, increasing treatment effectiveness and overcoming antigen immune escape.

BIOMEDICINES (2022)

Add to Collection

Review Oncology

Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy

Flavia Linguanti, Elisabetta Maria Abenavoli, Valentina Berti, Egesta Lopci

Summary: Chimeric antigen receptor-engineered T cells are a promising therapy for refractory/relapsed B-cell lymphomas. This review discusses the use of [F-18]FDG PET/CT in CAR-T cell therapy, focusing on its role in predicting treatment response and assessing metabolic parameters. The literature suggests that metabolic tumor burden is a valuable predictor of disease progression and overall survival, while 1 month PET/CT is the preferred time point for post-therapy evaluation. In addition, PET/CT brain scans are emerging as a useful tool for evaluating neurotoxicity related to CAR-T therapies. Overall, PET/CT is an accurate method for assessing treatment response and predicting outcomes in CAR-T treatment.

CANCERS (2022)

Add to Collection

Article Immunology

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Paolo F. Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, Folashade Otegbeye, Nausheen Ahmed, Patricio Rojas, Seema Patel, Sarah Kleinsorge Block, Jennifer Schiavone, Kayla Zamborsky, Kirsten Boughan, Antoinette Hillian, Jane Reese-Koc, Mikhail Maschan, Boro Dropulic, Rafick-Pierre Sekaly, Marcos De Lima

Summary: In this study, the efficacy of anti-CD19 CAR-T cells in treating relapsed/refractory lymphoma patients was investigated. Prophylactic use of tocilizumab was found to reduce the incidence and severity of cytokine release syndrome, without increasing the frequency or severity of ICANS, leading to improved treatment outcomes and survival rates for patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell Lymphomas

Stephen J. Schuster

Summary: CAR T cells, genetically engineered to produce artificial receptors on their surface, have shown promising results in achieving long-term, disease-free survival in certain lymphoma patients and addressing the unmet need for new treatments. Three commercially available CAR T-cell products have demonstrated efficacy in relapsed or refractory DLBCL, transformed follicular lymphoma, and primary mediastinal large B-cell lymphoma.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Hematology

Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas

Anna Dodero, Stefania Bramanti, Martina Di Trani, Martina Pennisi, Silva Ljevar, Annalisa Chiappella, Magagnoli Massimo, Anna Guidetti, Francesco Corrado, Paulina Maria Nierychlewska, Alice Di Rocco, Daniele Lorenzini, Rahal Daoud, Chiara De Philippis, Armando Santoro, Carmelo Carlo-Stella, Paolo Corradini

Summary: This study evaluated the outcome of salvage therapy in 51 patients with relapsed/refractory large B-cell lymphomas who failed axicabtagene ciloleucel or tisagenlecleucel. The study found that patients with high circulating tumor DNA (ctDNA) levels had poor outcomes. Factors adversely affecting the prognosis were the absence of response to CAR T-cell therapy and a diagnosis other than primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (t-FL).

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas

Sylvia Hartmann, Sonja Scharf, Yvonne Steiner, Andreas G. Loth, Emmanuel Donnadieu, Nadine Flinner, Viola Poeschel, Stephanie Angel, Moritz Bewarder, Julia Bein, Uta Brunnberg, Alessandro Bozzato, Bernhard Schick, Stephan Stilgenbauer, Rainer M. Bohle, Lorenz Thurner, Martin-Leo Hansmann

Summary: This study systematically analyzed the differences in dynamic behavior of lymphoma and bystander cells between different lymphoma types, showing variations in cell velocity and contact duration between B cells and PD1-positive T cells. Hodgkin lymphomas were found to have fast moving PD1-positive T cells, while there was little movement in other lymphoma types. Additionally, differences were observed in the duration of cell contacts, with mantle cell lymphoma showing short contact times and nodular lymphocyte-predominant Hodgkin lymphoma presenting prolonged contact times.

CANCERS (2021)

Add to Collection

Article Oncology

Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas

Daniel J. Landsburg, Alexa Koike, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Mariusz A. Wasik, Gabriel C. Caponetti

Summary: The study revealed frequent overexpression of immune checkpoint proteins in tumor tissue from patients with MYC-overexpressing DLBCL and BCLU/HGBL, with differences in overexpression patterns based on MYC-R status. These findings provide a biological rationale for investigating the use of checkpoint inhibitor therapies in these subgroups.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Yang Wu, Dan Chen, Ya Lu, Shu-Chen Dong, Rong Ma, Wei-yan Tang, Jian-qiu Wu, Ji-Feng Feng, Jian-Zhong Wu

Summary: The study demonstrated an effective CAR-T cell treatment for CD30-positive PTCL tumors by using CD30 CAR T cells to suppress tumor growth.

CANCER GENE THERAPY (2022)

Add to Collection

Article Oncology

Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case Series

Pietro Torre, Annalisa Brescia, Giorgio Giurato, Raffaella D'Auria, Francesca Rizzo, Benedetta Maria Motta, Valentina Giudice, Carmine Selleri, Pio Zeppa, Alessandro Caputo, Vincenzo Casolaro, Marcello Persico

Summary: MAIT cells are frequently found in T-cell lymphomas, and further in-depth studies with a larger number of samples are needed to better clarify the contribution of MAIT cells to this rare neoplasm.

CANCERS (2022)

Add to Collection

Article Oncology

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

Beatrice Casadei, Lisa Argnani, Serafina Guadagnuolo, Cinzia Pellegrini, Vittorio Stefoni, Alessandro Broccoli, Laura Nanni, Alice Morigi, Ginevra Lolli, Maria Guarino, Luca Spinardi, Elisabetta Pierucci, Stefano Fanti, Michele Bartoletti, Michele Dicataldo, Elena Sabattini, Francesca Bonifazi, Pier Luigi Zinzani

Summary: Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma, and CD19 CAR T-cell therapies have been approved for treating relapsed/refractory LBCL patients, showing a manageable safety profile and high objective response rate in the standard of care setting.

CANCERS (2021)

Add to Collection

Review Hematology

Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature

Santiago Mercadal, Carlos A. Gomez, Catherine J. Lee, Daniel R. Couriel

Summary: Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed B-cell non-Hodgkin lymphoma (NHL). However, infections are common after CAR-T treatment, especially in patients with more than 4 prior antitumor regimens and patients aged 65 or above. Fungal infections, including fatal disseminated candidiasis and invasive pulmonary aspergillosis, carry significant morbidity and mortality. Increased fungal surveillance and anti-mold prophylaxis may be necessary in these cases. Some patients developed a antibody response following SARS-CoV-2 mRNA vaccination.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Review Health Care Sciences & Services

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma

Magdalena Ostojska, Emilia Nowak, Julia Twardowska, Monika Lejman, Joanna Zawitkowska

Summary: Non-Hodgkin lymphomas (NHL) is a type of cancer originating from the lymphatic system, and it is the fourth most common cancer among pediatric patients. Available medicines and therapies have improved the prognosis for NHL patients, but treatment resistance remains a challenge. Immunotherapy, specifically chimeric antigen receptor (CAR) T cell therapy, is becoming increasingly important as a targeted and personalized treatment strategy for pediatric patients with NHL. This review evaluates the effectiveness, safety, and limitations of CAR-T cell therapy.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Add to Collection

Article Hematology

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Mazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, Yue Chen, Cameron J. Turtle, Peiman Hematti, Jonathon B. Cohen, Farhad Khimani, Siddhartha Ganguly, Reid W. Merryman, Jean A. Yared, Frederick L. Locke, Nausheen Ahmed, Pashna N. Munshi, Amer Beitinjaneh, Patrick M. Reagan, Alex F. Herrera, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani

Summary: The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is not known. A study found that auto-HCT treatment was associated with a lower rate of relapse and superior overall survival compared to CAR-T treatment in DLBCL patients in PR after salvage therapy. These findings support auto-HCT as the standard of care for transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.

BLOOD (2022)

Add to Collection

Article Hematology

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

Krishna R. Juluri, Qian Vicky Wu, Jenna Voutsinas, Jue Hou, Alexandre Hirayama, Erin Mullane, Nancy Miles, David G. Maloney, Cameron J. Turtle, Merav Bar, Jordan Gauthier

Summary: CD19-targeted CAR T-cell therapy has shown significant efficacy in patients with B-cell malignancies, but is associated with toxicities such as CRS and neurotoxicity. Research suggests that the severity of CRS and prelymphodepletion platelet count are independent predictors of hematologic toxicity.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Jordan Gauthier, Nicolas Gazeau, Alexandre Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A. Chow, Ajay K. Gopal, Alexandria Hodges Dwinal, Staci Williamson, Jessie Myers, Andy Chen, Sarah Nagle, Brandon Hayes-Lattin, Levanto Schachter, David G. Maloney, Cameron J. Turtle, Mohamed L. Sorror, Richard T. Maziarz

Summary: The type of CD19 CAR T-cell product independently affects the toxicity and efficacy in patients with relapsed or refractory aggressive B-NHL.

BLOOD (2022)

Add to Collection

Article Oncology

Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma

Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, Erin Mullane, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Stephen D. Smith, Ajay K. Gopal, Christina Poh, Lorenzo Iovino, Cameron J. Turtle, David G. Maloney, Brian G. Till, Jordan Gauthier, Mazyar Shadman

Summary: Cytopenias following CAR-T therapy are important adverse events that have been less studied. Our analysis of patients with large cell lymphoma receiving axi-cel revealed that severe cytopenias were observed in a high percentage of patients, particularly among non-responders.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Surgery

Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy

Joshua A. Hill, Erika S. Kiem, Atif Bhatti, Winnie Liu, Jacob Keane-Candib, Kristin S. Fitzpatrick, Jim Boonyaratanakornkit, Rebecca A. Gardner, Damian J. Green, David G. Maloney, Cameron J. Turtle, Jodi M. Smith, Idoia Gimferrer, Christopher D. Blosser, Shaun W. Jackson

Summary: The presence of anti-HLA antibodies hinders successful organ transplantation. B cell-depleting treatments have limited effectiveness in reducing these antibodies. This study suggests that long-lived plasma cells, not effectively targeted by B cell depletion, are the primary source of anti-HLA antibodies. Plasma cell-targeted therapies may be more effective in managing HLA antibodies and improving access to organ transplantation.

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Add to Collection

Meeting Abstract Hematology

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Ivan J. Huang, Rosa Yeh, Karen Sweiss, Pritesh Patel, Alexandre Vinaud Hirayama, Erik L. Kimble, Krishna R. Juluri, Mazyar Shadman, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Krina Patel, Nina Shah, Alan Tan, Andrew J. Cowan, Cameron J. Turtle, Craig C. Hofmeister, Taewoong Choi, Hayder Saeed, Julio C. Chavez, Matthew J. Pianko, Mitul Gandhi, Sohail A. Chaudhry, Zachary Lee, Neha Dixit, Christie Fanton, Xiaoli Wang, Heng Xu, Mario Q. Marcondes, Mary A. Tagliaferri, Jonathan Zalevsky, Miguel-Angel Perales

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Alexandre Vinaud Hirayama, Cassie Chou, David G. Maloney, Mario Q. Marcondes, Cameron J. Turtle

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study

Nicolas Gazeau, Salvatore Fiorenza, Erik L. Kimble, Alexandre Vinaud Hirayama, Barbara S. Pender, Henna A. Di, Delaney R. Kirchmeier, Brian G. Till, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle, Jordan Gauthier

BLOOD (2022)

Add to Collection

Article Cell Biology

Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study

Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, Lorena Panaite, Erin Mullane, Ryan C. Lynch, Chaitra Ujjani, Stephen D. Smith, Ajay K. Gopal, Brian G. Till, Filippo Milano, Victor Chow, Jordan Gauthier, Cameron J. Turtle, David G. Maloney, Mazyar Shadman

Summary: This single-institution study analyzed the impact of multiple variables on the outcomes of CAR-T therapy. The study showed that CAR-T treatment should be continued for DLBCL patients who do not respond to immediate pre-CAR-T therapy. Additionally, bulky disease and high LDH are risk factors for poor treatment outcomes.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2022)

Add to Collection

Article Hematology

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy

Alexandre Hirayama, Cassie K. Chou, Takahiro Miyazaki, Rachel N. Steinmetz, Henna A. Di, Simon P. Fraessle, Jordan Gauthier, Salvatore Fiorenza, Reed M. Hawkins, Willem W. Overwijk, Stanley R. Riddell, Mario Q. Marcondes, Cameron J. Turtle

Summary: CAR T-cell therapy has shown efficacy in treating relapsed/refractory B-cell malignancies, but durable responses are limited. NKTR-255, a polymer-conjugated IL-15, enhances in vivo proliferation of T cells and NK cells, and improves the antitumor efficacy of CD19 CAR T cells. These findings support an ongoing phase 1 clinical trial of combined therapy with CD19 CAR T cells and NKTR-255 for relapsed/refractory B-cell malignancies.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Nicolas Gazeau, Emily C. Liang, Qian Vicky Wu, Jenna M. Voutsinas, Pere Barba, Gloria Iacoboni, Mi Kwon, Juan Luis Reguera Ortega, Lucia Lopez-Corral, Rafael Hernani, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Antonio Perez Martinez, Richard T. Maziarz, Staci Williamson, Eneida R. Nemecek, Mazyar Shadman, Andrew J. Cowan, Damian J. Green, Erik Kimble, Alexandre Hirayama, David G. Maloney, Cameron J. Turtle, Jordan Gauthier

Summary: This study retrospectively analyzed the outcomes of 43 patients with B cell or plasma cell malignancies treated with anakinra for refractory CRS or ICANS after CAR-T therapy. The results showed that anakinra treatment is safe and feasible, with limited impact on CAR-T efficacy. Higher anakinra dose may be associated with faster CRS/ICANS resolution and lower treatment-related mortality.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Article Oncology

gamma-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-inhuman trial

Andrew J. Cowan, Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby, David G. Coffey, Sherilyn A. Tuazon, Brent Wood, Ted Gooley, Vicky Q. Wu, Jenna Voutsinas, Xiaoling Song, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green

Summary: Background: Gamma-secretase inhibitors (GSIs) can increase B cell maturation antigen (BCMA) density on malignant plasma cells and enhance the anti-tumor activity of BCMA chimeric antigen receptor (CAR) T cells. This study aimed to evaluate the safety and determine the recommended phase 2 dose of BCMA CAR T cells in combination with crenigacestat for relapsed or refractory multiple myeloma patients. Methods: A phase 1 trial was conducted, combining crenigacestat with BCMA CAR T cells at a cancer center in Seattle, USA. Findings: 19 participants were enrolled, and 18 multiple myeloma patients received treatment. The most common grade 3 or higher non-hematological adverse events included hypophosphatemia, fatigue, hypocalcemia, and hypertension. The recommended phase 2 dose was not reached. Interpretations: Combining a GSI with BCMA CAR T cells appears to be well tolerated and increases target antigen density. Further study is warranted to investigate the use of GSIs with BCMA-targeted therapeutics in clinical trials.

LANCET ONCOLOGY (2023)

Add to Collection

Meeting Abstract Hematology

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C. Pasquini, Cameron J. Turtle

BLOOD (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.